Susquehanna International Group
CADL icon

Susquehanna International Group’s Candel Therapeutics CADL Stock Holding History

Susquehanna International Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$814K Buy
166,100
+135,600
+445% +$738K ﹤0.01% 8428
2025
Q4 		$172K Sell
30,500
-48,300
-61% -$260K ﹤0.01% 11032
2025
Q3 		$402K Sell
78,800
-39,100
-33% -$226K ﹤0.01% 9463
2025
Q2 		$597K Sell
117,900
-91,800
-44% -$472K ﹤0.01% 8775
2025
Q1 		$1.18M Sell
209,700
-451,800
-68% -$3.69M ﹤0.01% 6826
2024
Q4 		$5.74M Buy
661,500
+637,900
+2,703% +$3.77M ﹤0.01% 3393
2024
Q3 		$164K Buy
23,600
+900
+4% +$5.59K ﹤0.01% 10662
2024
Q2 		$141K Buy
+22,700
New +$170K ﹤0.01% 10764

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's CADL Position: Q1 2026 in Review

Susquehanna International Group reduced its Candel Therapeutics (CADL) stake by 18% in Q1 2026, selling an estimated $133K and leaving 112,973 shares worth $554K. The position accounts for ﹤0.01% of the portfolio, ranked #9392.

Susquehanna International Group first reported a position in CADL in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.56M in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Susquehanna International Group held 112,973 shares of Candel Therapeutics worth $554K as of Q1 2026.
  • Susquehanna International Group sold 24,435 Candel Therapeutics shares in Q1 2026, an estimated $133K.
  • Candel Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9392 holding.
  • Susquehanna International Group first reported a position in Candel Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Susquehanna International Group's Candel Therapeutics position peaked at $2.56M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.